Ad5 EBOV DNA vaccine

Drug Profile

Ad5 EBOV DNA vaccine

Alternative Names: Ad5 EBOV vaccine Academy of Military Medical Sciences/Tianjin CanSino; Ad5 vector based Ebola vaccine Academy of Military Medical Sciences/Tianjin CanSino; Ad5-EBOV; Ebola adenovirus vector vaccine - Academy of Military Medical Sciences/Tianjin CanSino; Ebola adenovirus vector vaccine - Tianjin CanSino/Academy of Military Medical Sciences; Ebola Zaire vaccine - Academy of Military Medical Sciences/Tianjin CanSino; Ebola Zaire vaccine - Tianjin CanSino/Academy of Military Medical Sciences

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Academy of Military Medical Sciences; Tianjin CanSino Biotechnology
  • Developer Academy of Military Medical Sciences; Beijing Institute of Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention; Tianjin CanSino Biotechnology; Zhejiang University
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ebola virus infections

Most Recent Events

  • 01 Jul 2016 Jiangsu Province Centers for Disease Control and Prevention completes a phase-II trial in Ebola virus infections (Prevention) in Sierra Leone (IM) (NCT02575456)
  • 13 Oct 2015 Phase-II clinical trials in Ebola virus infections (Prevention) in Sierra Leone (IM) (NCT02575456)
  • 01 Jul 2015 Tianjin CanSino initiates enrolment in a phase I trial for Ebola virus infection (In volunteers) in China (NCT02533791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top